BioCombo Therapeutics

BioCombo Therapeutics (博创生物) is a Jiangsu-based biomedical company developing high-performance bioengineered tissue membranes and derived medical devices, founded by CEO Tan Haoqi (谈浩琪) to commercialize more than a decade of research from the team of Academician Liu Changsheng at East China University of Science and Technology . The company's core innovation is a proprietary electrochemical deposition (EDP) technology platform, positioned as a first-in-class alternative to mainstream approaches like decellularized tissue matrices and electrospinning, which it claims can overcome limitations in structural precision, cost, and production efficiency . Dalton Venture invested in BioCombo at the angel round stage, with the firm later listing it among its 2023 portfolio companies alongside medtech peers in neurointervention, endoscopy, and surgical robotics . At Dalton Venture's 2025 CEO Summit, Tan noted that while 1,138 collagen-based medical devices are approved in China, high-end functional implants account for less than 1% of the market, a gap BioCombo aims to address by replicating natural tissue microstructure more closely than synthetic alternatives .